Concentration-dependent rheological properties of ECM hydrogel for intracerebral delivery to a stroke cavity.

Andre R. Massensini, Ph.D.^{1,3,7#}; Harmanvir Ghuman, B.Sc.^{1,2#},

Lindsey T. Saldin, B.Sc.^{1,2}, Christopher J. Medberry, Ph.D.^{1,2};

Timothy J. Keane, B.Sc.^{1,2}, Francesca J. Nicholls, Ph.D.^{1,3,6},

Sachin S. Velankar, Ph.D.^{1,4}, Stephen F. Badylak, D.V.M., Ph.D., M.D.^{1,2,5};

Michel Modo, Ph.D.^{1,2,3*}

Both authors contributed equally

University of Pittsburgh, ¹McGowan Institute for Regenerative Medicine, ²Department of Bioengineering, ³Department of Radiology, ⁴Department of Chemical Engineering, ⁵Department of Surgery, Pittsburgh, Pennsylvania, USA; ⁶King's College London, Department of Neuroscience, London, UK; ⁷Universidade Federal de Minas Gerais, Department of Physiology and Biophysics, Belo Horizonte, Brazil. Tel: (412) 383-7200; FAX: (412) 647-0878

***Corresponding Author:**

Dr. Mike Modo
University of Pittsburgh
McGowan Institute for Regenerative Medicine
3025 East Carson St
Pittsburgh, PA 15203
USA
+1 (412) 383 7200
e-mail: modomm@upmc.edu

Abstract

Biomaterials composed of mammalian extracellular matrix (ECM) promote constructive tissue remodeling with minimal scar tissue formation in many anatomical sites. However, the optimal shape and form of ECM scaffold for each clinical application can vary markedly. ECM hydrogels have been shown to promote chemotaxis and differentiation of neuronal stem cells, but minimally invasive delivery of such scaffold materials to the central nervous system (CNS) would require an injectable form. These ECM materials can be manufactured to exist in fluid phase at room temperature, while forming hydrogels at body temperature in a concentration-dependent fashion. Implantation into the lesion cavity after a stroke could hence provide a means to support endogenous repair mechanisms. Herein, we characterize the rheological properties of an ECM hydrogel composed of urinary bladder matrix (UBM) that influence its delivery and in vivo interaction with host tissue. There was a notable concentration-dependence in viscosity, stiffness, and elasticity; all characteristics important for minimally invasive intracerebral delivery. An efficient MRI-guided injection with drainage of fluid from the cavity is described to assess in situ hydrogel formation and ECM retention at different concentrations (0, 1, 2, 3, 4, and 8 mg/mL). Only ECM concentrations >3 mg/mL gelled within the stroke cavity. Lower concentrations were not retained within the cavity, but extensive permeation of the liquid phase ECM into the peri-infarct area was evident. The concentration of ECM hydrogel is hence an important factor affecting gelation, host-biomaterial interface, as well intra-lesion distribution.

Keywords: Biomaterial, Delivery, Extracellular matrix, Injection, Magnetic resonance imaging, Stereotactic, Brain, Stroke

1. Introduction

Therapeutic options for stroke remain very limited [1]. Most pharmacological agents are administered systemically during the acute phase to either resolve a thrombus or to provide neuroprotection. The focus of current therapy is the modulation of the remaining brain tissue response by systemic administration of agents or cells that putatively promote plasticity. In the absence of neuroprotection, cells in the infarct territory die, resulting in liquifactive necrosis and invading phagocytic cells that remove cellular debris and the surrounding tissue matrix [2]. A fluid-filled lesion cavity remains. A key challenge in the treatment of stroke is hence the removal of necrotic debris and access to the adjacent viable or potentially viable tissue.

The advent of regenerative medicine affords potentially novel strategies for integration of endogenous or exogenous cells and/or therapeutic agents/materials into the damaged brain by intracerebral injection [3-5]. Studies have shown that injecting cells directly into the lesion cavity results in their migration into the existing parenchyma with poor survival [6]. These exogenously delivered cells by themselves do not replace lost tissue. To achieve retention of injected cells within the lesion cavity, it is essential to provide a permissive structural and functional microenvironmental niche [6-9]. Such niche support may be achieved by biomaterials specifically engineered to be compatible with neural tissue and amenable to delivery through a small gauge needle for intracerebral injections, with minimal damage to healthy tissue [1, 4, 10]. Hydrogel forms of naturally occurring biomaterials composed of extracellular matrix (ECM) show in

vitro chemoattraction and differentiation stimuli for neural stem cells [11-13]. ECM hydrogels are rapidly infiltrated by pan (CD68+) macrophages, which likely participate in hydrogel degradation [14]. Perhaps most importantly, ECM hydrogels have been shown to promote the M2 “constructive remodeling” macrophage phenotype, characterized as scavenging debris, promoting angiogenesis and recruiting cells involved in constructive tissue remodeling [15, 16]. Therefore, ECM hydrogels may supply growth factors, mechanical properties, and/or signaling molecules to support delivered cells; or support surviving endogenous cells and obviate the need for exogenous cells. [5, 17-19]. Rheological characterization of an ECM hydrogel intended for CNS applications is essential for an effective evaluation of delivery, safety and efficacy of this therapeutic strategy [20].

The ECM concentration affects rheological properties and determines if it will form a hydrogel or remain in a liquid phase [21]. Without the formation of a gel phase in situ, the ECM will diffuse and not provide a structural support within the lesion cavity [22]. Additionally, the stiffness of hydrogel will influence cell invasion and phenotypic choice of neural progenitors [23, 24]. Determining the rheological properties of ECM hydrogels is therefore important to establish the retention of scaffolding material within the lesion cavity and the associated host response. As lesion cavities caused by ischemic stroke may consist of a large volume and irregular shape, it is essential to ensure that administration is indeed into the tissue void rather than intraparenchymally, where this volume would cause tissue disruption and potentially increased intracerebral pressure [25, 26].

The use of non-invasive imaging, such as magnetic resonance imaging (MRI), can guide the volume of injection, as well as its stereotactic location, to ensure the safety of this approach [27, 28].

The objective of the present study was to characterize the concentration-dependent rheological properties of an ECM hydrogel, specifically an ECM hydrogel composed of urinary bladder matrix (UBM)-ECM, for the intended clinical application of minimally invasive intracerebral injection. To assay the in situ gel formation based on the concentration-dependent properties of the ECM, we also describe an innovative neurosurgical approach for its delivery in the liquid phase into the stroke cavity using MRI guidance.

2. Methods

2.1. Extracellular matrix (ECM)-based hydrogel

The ECM material is composed of the basement membrane and tunica propria of porcine urinary bladder (Tissue Source, Inc., Lafayette, IN). The material was prepared by mechanical delamination of the remaining luminal epithelium and subjacent layers, followed by decellularization by exposure to 0.1% peracetic acid in 4% ethanol (v/v; 120 min; 300 rpm) with agitation followed by a series of PBS and deionized water rinses [21]. Decellularization was confirmed using Hematoxylin & Eosin, 4',6-diamidino-2-phenylindole (DAPI) staining, agarose gel electrophoresis, and quantification of remnant DNA [29]. The remaining ECM was identified as urinary bladder matrix (UBM), and was then lyophilized,

comminuted, solubilized with pepsin (1 mg/mL) in 0.01 N HCl and neutralized with 0.1 N NaOH with dilution to a desired concentration (1, 2, 3, 4, 8 mg/mL) in PBS [21]. A 0 mg/mL condition consisting of only PBS served as a control.

The final product was an injectable liquid at room temperature (21 °C). Concentration and intracerebral temperature determine the rate of hydrogel formation and the rheological and turbidimetric characteristics of the hydrogel [30, 31] which were extensively characterized previously [21]. A concentration >3 mg/mL is required for the formation of hydrogel; below this concentration insufficient gelation is observed. Importantly, if the injectate is excessively diluted within the extracellular fluid (ECF), gelation kinetics and distribution within the lesion can be affected [22, 32]. Being able to accurately determine the volume for injection, as well as being able to drain the ECF, is therefore essential to ensure a lesion-specific distribution and robust gelation within the cavity. The rheological properties of hydrogel are important to determine the biophysical interaction with the host tissue.

2.2 ECM hydrogel rheology

All rheological data was collected using a rheometer (AR2000, TA instruments, New Castle, DE) fitted with 40 mm parallel plate geometry, as previously described [21, 30, 31] and analyzed using the American Society for Testing and Materials (ASTM) standard F2900-11 (Guide for characterization of hydrogels used in regenerative medicine). Temperature was controlled within 0.1 °C using a Peltier plate. At 10 °C, a temperature at which the rate of gelation is negligible,

the gel precursor was loaded onto the parallel plate rheometer. Sample evaporation was minimized using mineral oil to seal the edges of the sample-plate interface.

A series of rheological tests were conducted in sequence for each sample. A creep test was performed to measure the steady shear viscosity of the gel precursor by applying a constant shear stress of 1 Pa. An oscillatory time sweep was performed to measure the gelation kinetics of the forming ECM hydrogel by rapidly raising the temperature to 37 °C (a temperature at which ECM gelation occurs) and applying a small 0.5% oscillatory strain at a frequency of 1 rad/s. After 40-60 minutes when the gelation was deemed complete, an oscillatory frequency sweep was performed to measure the complex viscosity ($|\eta^*|$) over a frequency range (0.1 rad/s – 100 rad/s) by applying 0.5% oscillatory strain. Samples were evaluated in triplicate.

2.3. Middle Cerebral Artery Occlusion (MCAo)

All animal procedures complied with the US Animals Welfare Act (2010) and were approved by the University of Pittsburgh Institutional Animal Care and Use Committee (IACUC). Male Sprague-Dawley rats (260±15 g, Taconic Labs, USA) were maintained on a 12 hour light/dark schedule, with food and water available *ad libitum*. For transient intraluminal right middle cerebral artery (MCA) occlusion, a rat model of stroke, a 5-0 silicon rubber-coated monofilament (diameter 0.12 mm, length 30 mm, tip coating at 0.35 mm for 5-6 mm, 503556PK10, Doccol, USA) was advanced to the ostium of the MCA in the circle of Willis under

isoflurane (4% induction, 1% maintenance in 30% O₂) anesthesia. The MCA was occluded for 70 minutes prior to reperfusion by retracting the filament to the common carotid bifurcation. After recovery from anesthesia, animals were assessed for forelimb flexion and contralateral circling with daily post-operative care and neurological assessment until they recovered pre-operative weight [33].

2.4. Magnetic Resonance Imaging (MRI) and infarct volume calculation

Twelve days after MCAo, rats were anesthetized with isoflurane (4% induction, 1% maintenance) to assess the presence, location and volume of tissue loss using a T₂-weighted spin-echo MRI sequence (TR = 6000 ms, TE = 8 ms, 8 Averages, FOV 30x30 mm, 128x128 matrix, 42 slices at 0.5 mm thickness) on a horizontal bore 9.4 T Varian scanner. Tissue volume loss was based on a hyperintense signal on T₂-weighted images that were thresholded at 1 standard deviation above the mean of a rectangular region of interest (ROI) in the contralateral hemisphere, encompassing striatum, corpus callosum and neocortex [2, 34]. Rats (n=30) with lesion volume >40 mm³ (i.e. 40 µl) were selected for injections. The injection volume of biomaterial was equivalent to the lesion volume as determined by the hyperintense volume range on MR images (40-180 µl). A larger volume of material can be injected, as long as drainage of material from the cavity is sufficient.

2.5. Stereotactic coordinates for injection and drainage sites

Injection of biomaterials into the lesion cavity has mainly been achieved by

administering a high concentration of injectate that is then diluted by the extracellular fluid (ECF) present within the cavity [7, 11, 35]. Although certain biomaterials that are composed of solid particles will distribute throughout the ECF [7], the distance between particles will vary depending on the volume dilution and too large a distance may negate their function as a structural support. Solubilized extracellular matrix (ECM) and other materials require a certain minimum concentration to form a hydrogel in situ [21], otherwise the material will merely diffuse into the tissue parenchyma, rather than being retained within the cavity [22, 32] (Figure 1A). Merely increasing the volume of injection is problematic, as this will lead to an increase in intracerebral pressure (ICP), compromising the remaining tissue. There is further a risk of biomaterial escaping the lesion cavity and, for instance, occluding ventricular space preventing normal flow of cerebrospinal fluid (Figure 1B). In the brain, the trajectory of injection also needs to avoid damage to major anatomical structures and placement needs to be accurate to avoid damage to host tissue (Figure 1C). Detailed neurosurgical planning, in combination with delivery of an appropriate concentration of biomaterial, is hence required to maximize the potential of biomaterial therapy for CNS repair [4].

Intracerebral delivery of biomaterials can either be achieved by dilution of the material in the extracellular fluid (ECF) available in the tissue cavity or this fluid can be drained during injection and a complete replacement of the milieu can be achieved (Figure 2A). To define 3-dimensional coordinates for stereotactic injection of biomaterials and drainage of ECF, MR images were compared to the

rat brain atlas [36] (Figure 2B). The MRI slice corresponding to Bregma was identified and based on slice thickness with the anterior and posterior limits of the tissue being determined [27]. For a dilution injection, the geometric center of the cavity was targeted, as previously described [27].

For an injection-drainage approach, coordinates targeted the posterior third of the lesion with a ventral location of the needle for injection. In contrast, drainage was aimed at the anterior third of the cavity with a dorsal placement of the cannula to allow near complete drainage of displaced ECF. As the biomaterial injectate is denser than ECF, it will cause ECF displacement extracranially. Special consideration in choosing coordinates is given to avoid juxtaposition of injection and drainage (at least 1 mm apart), preventing additive tissue damage in overlying cortex and potential direct drainage of injectate. An additional consideration in choosing coordinates was a potential mechanical disturbance of the lesion edge through closeness of injection/drainage. Anterior-posterior coordinates were hence chosen based on the extent of the tissue cavity and measuring the distance of this MRI slice in relation to the Bregma slice (based on MRI slice thickness). Lateral coordinates were defined to be central to the lesion within the injection/drainage slice in relation to the midline for +/- coordinates. Ventral positioning on MRI scans were defined based on the distance of the target site in relation to the top of the neocortex.

2.6. Implantation procedure

Fourteen days post-MCAo, rats underwent the implantation procedure by

placement into a stereotactic frame (Kopf, USA) under isoflurane anesthesia (1.5% in 30% O₂) prior to drilling of burr holes at the appropriate coordinates (Figure 2C) using a frame-mounted drill. The ECM was taken-up into a 250 µl Hamilton syringe with a 24 G beveled tip metal needle (Hamilton) mounted on the frame. The syringe/needle was advanced to the appropriate coordinates for biomaterial injection, whereas a 24 G cannula was placed in position to drain ECF. Needles/cannula were slowly lowered into brain tissue. Injection of biomaterial (0 , 1, 2, 3, 4, 8 mg/mL concentrations, n=5 per condition) was controlled using a frame mounted injection pump (World Precision Instruments, USA) at a constant speed of 10 µL/min until the total volume (40-180 µL) was delivered (7-17 min). The displacement of ECF from the lesion was evident and could be observed emerging from the drainage cannula (Figure 2D). For a no drainage condition, a single site of injection in the geometrical center of the lesion was applied (only 8 mg/mL concentration for comparison, n=5). After the injection was complete, the needle and cannula were left in place for 5 minutes before being slowly removed from the brain with burr holes being filled with bone wax (Fisher) prior to suturing. LX4 (Ferndale, containing 4% Lidocaine) was topically applied as an analgesic.

2.7. Intracranial pressure measurement

Injection of a large volume of biomaterial may cause an increase in intracranial pressure, which is known to have detrimental neurological effects [37]. A comparison of the injection-drainage technique with no drainage (both 8 mg/mL

ECM) was hence undertaken by monitoring intracranial pressure (ICP) during injections. A pressure sensor (WPI) attached to a fiber optic measurement system (RJC Enterprises) was used to measure ICP in mmHg. Prior to measurements, the probe was calibrated to atmospheric pressure (=0) and allowed to stabilize. For ICP measurement, a burr hole was made on the contralateral side at coordinates equivalent to the injection site. The probe was slowly inserted into the contralateral hemisphere to a depth of 5mm. Bone wax was then used to seal the burr hole around the probe. The injection/drainage needles were inserted and ICP was recorded at 15 s intervals throughout the injection. After injections were completed, the needles were left in place for 5min with continued ICP measurement.

2.8. Midline shift effects of intracerebral injections

A potential consequence of regional changes in intracranial pressure due to injection of a large volume of biomaterial is evident on morphological changes in tissue distribution. After stroke, it is known that there is a midline shift towards the lesion area [6]. This shift is typically reflective of differential hemispheric volumes that in an acute setting reflect the effect of edema [2]. The same principle can be applied to volumetric effects of biomaterial injected into one hemisphere increasing local intracranial pressure that is dissipated by hemispheric volume changes and/or a midline shift. Hemispheric areas and diameter were hence measured (Supplementary Figure 1A) using FIJI (NIH).

2.9. Histological Assessment

To analyze the distribution of the ECM hydrogel within the lesion cavity, rats were transcardially perfused with 0.9% saline followed by 4% paraformaldehyde (in 0.2 M PBS) 1 day post-implantation to fix brain tissue prior to its removal from the skull. Brains were post-fixed in 4% paraformaldehyde for 24 h prior to being cryopreserved in 30% sucrose with sodium azide (Sigma) at 4° C. Histological sections (50 µm thickness) were cut on a cryostat (Leica) directly onto microscopic slides. Brain sections were washed 3x10 minutes with 0.01 M PBS, followed by 1 hour permeabilization in PBS + 0.1% Triton X-100 (Sigma) at room temperature. Sections were then washed 3x10 minutes in PBS + 0.05% Triton X-100 followed by one hour in blocking solution (PBS + 0.05% Triton X-100 + 10% Normal Goat Serum, NGS, Vector). Primary antibodies were then applied, consisting of pig-specific mouse anti-collagen I (1:250, Millipore, MAB3391), a non-specific rabbit anti-collagen I antibody (1:250, Abcam, AB34710), goat anti-collagen IV (1:50, Millipore, ab769), sheep anti-hyaluronic acid (1:100, Abcam, ab53842), chicken anti-laminin (1:200, Abcam, ab14055), mouse anti-chondroitin sulfate (1:200, Abcam, ab11570), a mouse anti-Glial Fibrillary Acid Protein (GFAP, 1:3000, Sigma, G3893) and a goat anti-Iba1 (1:300; Abcam, ab5076) diluted in blocking solution (0.05% Triton X-100, 10% NGS in PBS) and incubated at 4° C overnight. After rinsing of the primary antibodies (3x20 min PBS), appropriate secondary Alexa Fluor 488 and 555 antibodies (Life Technologies) were applied for 1.5 hours prior to 3x5 min washes in PBS and being coverslipped with Vectashield for fluorescence containing DAPI (Vector

Laboratories). Visualization of antibodies was performed on a fluorescence microscope (Axioimager M2, Zeiss) interfaced with a monochrome camera driven by Stereo Investigator image capture software (MBF Bioscience). To measure the degree (%) coverage of the cavity by ECM injection, ROIs were drawn in FIJI to delineate the lesion cavity (based on Iba1 reactivity of the lesion edge) and the ECM hydrogel (based on collagen I staining, Supplementary Figure 1B).

Statistical Analyses

Statistical analyses were performed in SPSS 17 for Mac (IBM). Specifically, independent t-tests were used to compare rheological conditions. A non-parametric Kruskal Wallis test was performed to compare extent coverage of the lesion cavity by the ECM hydrogel followed by Dunn's post-hoc testing. A Pearson correlation coefficient was calculated between lesion volumes and ICP measurements. Statistical significance was set at a p value of <0.05. Graphs were drawn in Prism 6 (GraphPad) with data points representing the median and bars reflecting the value range. A post-hoc power analysis of the Kruskal Wallis was calculated in G*Power (version 3, University of Trier) for the amount of cavity coverage achieved by the ECM.

3. Results

3.1 Pre-gel viscosity and hydrogel stiffness is concentration-dependent

The rheological characteristics of the ECM hydrogel were determined before (10

°C) and after (37 °C) gelation was induced using a parallel plate rheometer. Preparations of less than 3 mg/ml did not exhibit a robust gelation and therefore did not afford a full rheological evaluation (data not shown). Before gelation, the viscosity of the 4 mg/mL ECM gel precursor was significantly ($p=0.001$) lower (0.084 ± 0.008 Pa*s) than the 8 mg/mL ECM gel precursor (0.443 ± 0.062 Pa*s) (Figure 3A). The storage modulus G' and loss modulus G'' of the 4 and 8 mg/mL ECM gels changed sigmoidally over time after temperature was raised from 10 °C to 37 °C (Figure 3B). At long times, the storage modulus at both concentrations far exceeded the loss modulus indicating substantially solid-like gels. The maximum storage modulus of the 8 mg/mL hydrogel (460.4 ± 62.5 Pa) was significantly ($p\leq0.001$) higher than the 4 mg/mL hydrogel (76.6 ± 10.4 Pa), as was the maximum loss modulus (66.4 ± 9.3 Pa, 11.0 ± 1.5 Pa, $p=0.008$) (Figure 3C). Half the maximum storage modulus ("50% gelation") marks the sharp increase in the storage modulus curve, and time to 50% gelation did not differ significantly between the 4 mg/mL (3.2 ± 0.3 minutes) and 8 mg/mL (3.0 ± 0.5 minutes) groups (Figure 3D). The fast gelation kinetics of the ECM hydrogel was further shown in that 15% of the final storage modulus was reached within 3-5 minutes for both gels (4 mg/mL in 3.9 ± 0.5 minutes and 8 mg/mL in 4.4 ± 0.5 minutes), where final storage modulus is defined as the average storage modulus over the last 10 minutes of the time sweep test. The frequency sweep of the ECM hydrogel is shown for 4 mg/mL (Figure 3E) and 8 mg/mL (Figure 3F). Both moduli are only weakly dependent on frequency, and therefore the complex viscosity varies almost inversely with frequency, further confirming the

predominantly solid-like nature of the gel. Indeed, the storage and loss modulus of the 4 mg/mL hydrogel was significantly lower than the 8 mg/mL hydrogel ($p \leq 0.001$) for the angular frequency range tested (0.1-100 rad/s). Both 4 and 8 mg/mL hence produce stable hydrogels in the same amount of time, but differ in their gel precursor viscosity, as well as their substrate stiffness.

3.2. Injection-drainage affords efficient delivery of ECM hydrogel

The delivery of 8 mg/mL hydrogel to the stroke cavity using a single injection point (i.e. no drainage) resulted in a 67% increase in intracranial pressure (ICP, Supplementary Figure 2A) with evidence of some material escaping the cranial vault past the needle used for injection. Using this no-drainage approach, it is hence difficult to control the exact concentration or volume of material being present within the cavity, as the injectate mixes with the fluid present in the cyst and it is not possible to control or monitor how much material seeps out. Injection with simultaneous drainage is hence proposed here as a superior method, where ICP only changed by 10% with excessive fluid from the cavity being displaced by the denser injected biomaterial. Indeed, in this case, excess fluid was drained extracranially through the additional cannula, rather than an uncontrolled escape along the injection needle. Importantly, in the injection-drainage condition, there was a negative correlation ($r = -0.98$, $p < .05$) between lesion volume and change in ICP, i.e. the larger the volume of the lesion, the less change in ICP, due to a greater space for accommodating the hydrogel. The opposite trend was evident in the no drainage condition ($r = 0.97$, $p = 0.07$) with larger volume of injections

leading to greater change in ICP. Although post-mortem (24 hrs) there was no significant midline shift (2-5%) in either condition, drainage resulted in 10% less hemispheric volume shift compared to no drainage. The increase in ICP, as well as hemispheric volume shift, hence indicates that drainage reduces potentially adverse effects of intracerebral injections on brain tissue.

3.3. Histological detection of ECM hydrogel

A histologic visualization of the injected ECM material was used to investigate and validate the distribution and retention of material within the lesion cavity. As porcine ECM hydrogels contain a higher concentration of collagen I compared to brain tissue, a pig-specific mouse anti-collagen I antibody afforded the selective identification of the implanted hydrogel (Figure 4A). In contrast, a non-specific rabbit anti-collagen I antibody detected both rat and pig collagen I. As ECM injection dramatically increased collagen I concentration, the exposure time used for image acquisition of the non-specific antibody can still selectively visualize the implanted materials (Figure 4B). The non-specific rabbit anti-collagen I reliably stained host collagen I, as indicated by its localization in the basement membrane of host blood vessels and its peri-infarct localization in MCAo+vehicle animals.

ECM also contains a variety of other molecules that putatively could serve for detection purposes inside the brain (Figure 5). ECM contains notably high levels of collagen IV, which is readily detecting the injected material, but is also highly expressed in glial scar tissue in the peri-infarct region. The same applies to

chondroitin sulfate, which is extensively present in the damaged hemisphere. Laminin also detects the injected material, but detection is not sufficiently specific as peri-infarct regions undergoing angiogenesis also express high levels. Although sensitivity is good for these markers, selectivity of ECM hydrogel visualization is poor. In contrast, Hyaluronic Acid (HA) contrasts sufficiently with host background and hence affords a specific macroscopic detection of the injected material akin to collagen I. Although HA is extensively present in brain tissue, the specificity of detection of the ECM hydrogel here is based on the abundance of HA within the scaffold in comparison to native tissue.

3.4. Reliability of ECM hydrogel delivery

Using the injection-drainage approach, the delivery of ECM hydrogel (8 mg/mL) to the stroke-induced lesion cavity successfully resulted in an extensive distribution of the biomaterial (as indicated by collagen I staining) throughout the lesion, while conforming to the topology of tissue loss (Figure 6A). There was a good correspondence between pre-implantation MRI and post-mortem immunohistochemistry (Figure 6B), indicating that the neurosurgical planning of the delivery location, as well as the volume were appropriate.

The formation of a hydrogel within the cavity at 8 mg/mL further indicates that an appropriate concentration of injectate was delivered throughout the lesion. Gelation typically resulted in the retention of ECM within the area of tissue loss, rather than permeation into the adjacent host brain tissue (Figure 7A). Nevertheless, in small areas at the edge of the cavity, ECM material could be

found in the host brain tissue where it gelled (Figure 7A i). There was no evidence of additional glial scarring in these regions. It is also worth noting that small hydrogel accumulations were evident in a few edge regions, where the gel did not completely replace the liquefied necrotic debris. Although the hydrogel conformed to the lesion topology, it is important to note that the 8 mg/mL ECM hydrogel was mostly distinct among the different ECM concentrations tested and did not invade adjacent brain tissue, with glial scarring being evident around most of the cavity. A small “bubble” without ECM hydrogel can occur (Figure 7A ii) if the drainage point is not at the most dorsal part of the cavity. However, this approach is very reproducible across different lesion sizes and topology (Figure 7B). Rheological and turbidimetric characteristics of the biomaterial will also influence intracerebral distribution. For instance, a faster and stiffer polymerization in the cavity can displace small tissue fragments to the periphery of the cavity or provide a sharply defined edge between ECM hydrogel and host tissue (Figure 7C). Gelation properties defined by the concentration of the material therefore also define the interface with the host brain.

3.5. Concentration-dependent retention of ECM within lesion cavity

Using the injection-drainage method, it is possible to deliver a specific volume and concentration of ECM to the lesion cavity and determine the effect of these variables upon its distribution, interface with the host brain, as well as its retention within the cavity (Figure 8A). Indeed, concentrations of <3 mg/mL did not form a robust enough gel within the lesion cavity to afford retention (Kruskall

Wallis = 27.02; $p < .001$; $1 - \beta = 0.87$), but rather showed permeation of ECM into the adjacent host brain (Supplementary Figure 2B). Permeation of ECM into the peri-infarct tissue results in a uniform extracellular distribution akin to tissue characteristics, such as striosomes, but is not associated with the basement membranes of blood vessels (Figure 8B). It is likely that some injected ECM material remained within the cavity, but this could not be determined by histologic methods. At 2 mg/mL, some small ECM accumulations within the cavity were evident (median 12; range 3-26% coverage). At 3 mg/mL, permeation into the host brain, as well as retention within the cavity, were evident (Figure 8C) with a more extensive coverage than the cavity (median 108; range 98-117%). At concentrations >3 mg/mL gelation and retention within the cavity occurred with little to no permeation into the host brain with 4 mg/mL achieving a 92% coverage (range 88-97%) and 8 mg/mL resulting in 89% of the cavity being filled with ECM (range 84-96%). The lower coverage of the 8 mg/mL is likely due to the formation of a more solid gel that did not interface as tightly with the brain tissue.

4. Discussion

The advent of cytocompatible and injectable biomaterials offers new opportunities to treat brain damage. However, access to the brain, as well as its rigid confinement within the skull [1, 4], pose technical challenges to define an adequate in situ hydrogel formation based on the concentration-dependent

rheological characteristics of ECM. The use of non-invasive imaging, such as MRI [28], ensures an efficient delivery of appropriate concentrations to assay gelation properties and their influence of ECM distribution in vivo. Herein, we describe the rheological characteristics of a urinary bladder matrix (UBM)-derived ECM hydrogel with the intended clinical application of minimally invasive intracerebral delivery and retention in stroke.

UBM is composed of the urothelial basement membrane and the subjacent tunica propria [38]. The basal membrane is comprised mainly of collagen IV and laminin. The tunica propria is comprised of collagen (I, III, IV, VI, and XII), elastin, the glycosaminoglycan hyaluronic acid, proteoglycans (e.g., decorin) and glycoproteins (e.g., fibronectin, osteopontin) [39]. Other peptides that may interact with cells include matricryptic peptides, growth factors, and cytokines [40]. A hydrogel composed of porcine urinary bladder ECM has been shown to be chemotactic for neural progenitor cells in vitro and to promote neural progenitor cell differentiation [12, 13, 30]. Porcine, rather than rat, material was used in the present study, because porcine ECM is used clinically for soft-tissue reconstruction in patients and there is greater abundance of tissue to process. There is little risk of cross-species contamination due to the removal of cellular antigens, and ECM proteins are well conserved across species [41].

It is noteworthy that ECM's rheological characteristics are based on concentration, time, and temperature [21]. A high concentration of ECM here (>3 mg/mL) afforded a robust and efficient formation of hydrogel that was retained within the lesion and an 8 mg/mL concentration approximated the 500-1000 Pa

elastic modulus of brain tissue [42-44]. These formulations are therefore desirable for delivery of agents without penetration of the host tissue [17, 19], but their retention within the cavity could structurally support cell delivery or attract host cell invasion to recolonize areas where tissue has been lost [5, 11, 45]. Gradual degradation of the hydrogel and replacement by host tissue would be expected. For instance, in a rat abdominal wall defect model, these ECM hydrogel almost completely degraded by 35 days, as shown by histology [43]. A radiolabeled small intestinal submucosa (SIS)-based ECM hydrogel in a dog model of urinary bladder repair further demonstrated that less than 10% of the starting material was present at 3 months post-surgery [31]. The mechanism by which ECM hydrogels promote constructive remodeling is by altering the default injury response [46-48] and by recruiting host tissue-specific stem/progenitor cells to the site of injury [49-51], eventually leading to the replacement of the injected material. However, the repair process, especially in the brain, remains poorly understood. Hence insufficient information is currently available to specifically engineer hydrogel degradation characteristics to match a particular repair time frame.

Using different concentration of ECM and a characterization of its biodegradation and cell infiltration response will help to improve our understanding of tissue repair. For instance, lowering the hydrogel ECM concentration (<3 mg/mL) might improve integration with the peri-infarct tissue and promote better interaction with host cells. If permeation of ECM hydrogel into the damaged peri-infarct proves to be of benefit, as with drug delivery, then

concentrations of ECM that do not gel or show a protracted gelation time would be desirable to afford permeation into tissue. There is some evidence that permeation of ECM into damaged brain tissue can lead to behavioral improvements [22]. Indeed, a concentration of 3 mg/mL in the present study resulted in both a permeation of ECM into the peri-infarct areas, as well as gelation and retention within the cavity. Still, the length of time required for hydrogel structural support for cell invasion and subsequent de novo tissue formation is unknown. As hydrogel stiffness, as well as inductive properties, can affect cell invasion and phenotype [13, 52, 53], it is essential to further characterize the short-term and long-term biological properties of the ECM formulations after injection in the stroke-damaged brain.

Although much effort is geared toward designing novel biomaterials or enhancing the biological effects of transplanted cells, little effort is devoted to the technical challenges associated with delivery of these therapeutics and its interaction with host tissue. Yet, there is ample evidence that biophysical considerations regarding delivery of therapeutics to the brain can dramatically influence their therapeutic effects [54]. Controlling cannula placement [55, 56] and size [57, 58], using an automated injection pump for consistent delivery [59, 60], as well as MRI guidance [27], have provided greater control over factors that can influence the delivery of therapeutics to the brain. The tuning of the rheological properties of ECM hydrogel that potentially can separate the stiffness of the gel from its inductive payload will provide further opportunities for the refinement of the in situ structure-function relationships required for therapeutic

success [40, 61-63]. An efficient local injection at an appropriate concentration will also be essential for the delivery of biomaterials that serve as local drug/cell delivery vehicles [8, 17, 18].

It was evident herein that the described approach mitigated potential adverse effects compared to injection of a large volume of a stiff material without drainage. However, the concentration-dependent effects presented here do only apply to ECM hydrogel, specifically the UBM hydrogel, with the presented rheological characteristics. ECM materials derived from other source tissues, or materials with different rheological properties will require similar in situ validation to determine their structure-function relationship that guides their interaction with the damaged host tissue.

5. Conclusion

Using the drainage-injection procedure, it will now be possible to better control the intra-cavity concentration of material and further optimize gelation parameters in situ in relation to the different biophysical and inductive properties of biomaterials. These steps are essential to provide a thorough preclinical evaluation of biomaterials, but also to define the technical challenges for clinical translation.

6. Acknowledgements

This study was funded by a seed grant from the Department of Health of the Commonwealth of Pennsylvania (4100061184) and the National Institute for Neurological Disease and Stroke (R01NS08226). ARM was supported by a Fellowship from CAPES Foundation, Brazil. CJM and LTS were partially supported by a NIH-NHLBI training grant (T32-EB001026, 2T32-EB001026-11, respectively). TJK was supported by the National Science Foundation Graduate Research Fellowship (DGE-1247842). SFB and MM gratefully acknowledge support from Vertex Pharmaceuticals. SSV acknowledges partial support from NSF-CMMI (1434674). We thank Dr Hiro Fukuda and Alex Poplawsky with their assistance to measure intracranial pressure and Dr Wen Ling for setting up the MRI scanning.

7. Disclosure

The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.

8. References

- [1] Modo M, Ambrosio F, Friedlander RM, Badylak SF, Wechsler LR. Bioengineering solutions for neural repair and recovery in stroke. *Current opinion in neurology* 2013;26:626-31.
- [2] Ashioti M, Beech JS, Lowe AS, Hesselink MB, Modo M, Williams SC. Multi-modal characterisation of the neocortical clip model of focal cerebral ischaemia by MRI, behaviour and immunohistochemistry. *Brain research* 2007;1145:177-89.
- [3] Kondziolka D, Steinberg GK, Cullen SB, McGrogan M. Evaluation of surgical techniques for neuronal cell transplantation used in patients with stroke. *Cell transplantation* 2004;13:749-54.
- [4] Meng F, Modo M, Badylak SF. Biologic scaffold for CNS repair. *Regenerative medicine* 2014;9:367-83.
- [5] Cheng TY, Chen MH, Chang WH, Huang MY, Wang TW. Neural stem cells encapsulated in a functionalized self-assembling peptide hydrogel for brain tissue engineering. *Biomaterials* 2013;34:2005-16.
- [6] Modo M, Stroemer RP, Tang E, Patel S, Hodges H. Effects of implantation site of stem cell grafts on behavioral recovery from stroke damage. *Stroke; a journal of cerebral circulation* 2002;33:2270-8.
- [7] Bible E, Chau DY, Alexander MR, Price J, Shakesheff KM, Modo M. The support of neural stem cells transplanted into stroke-induced brain cavities by PLGA particles. *Biomaterials* 2009;30:2985-94.
- [8] Jin K, Mao X, Xie L, Galvan V, Lai B, Wang Y, et al. Transplantation of human neural precursor cells in Matrigel scaffolding improves outcome from focal cerebral ischemia after delayed postischemic treatment in rats. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism* 2010;30:534-44.
- [9] Osanai T, Kuroda S, Yasuda H, Chiba Y, Maruichi K, Hokari M, et al. Noninvasive transplantation of bone marrow stromal cells for ischemic stroke: preliminary study with a thermoreversible gelation polymer hydrogel. *Neurosurgery* 2010;66:1140-7; discussion 7.
- [10] Wang J, Yang W, Xie H, Song Y, Li Y, Wang L. Ischemic stroke and repair: current trends in research and tissue engineering treatments. *Regen Med Res* 2014;2:3.
- [11] Bible E, Dell'Acqua F, Solanky B, Balducci A, Crapo PM, Badylak SF, et al. Non-invasive imaging of transplanted human neural stem cells and ECM scaffold remodeling in the stroke-damaged rat brain by (19)F- and diffusion-MRI. *Biomaterials* 2012;33:2858-71.
- [12] Crapo PM, Medberry CJ, Reing JE, Tottey S, van der Merwe Y, Jones KE, et al. Biologic scaffolds composed of central nervous system extracellular matrix. *Biomaterials* 2012;33:3539-47.
- [13] Crapo PM, Tottey S, Slivka PF, Badylak SF. Effects of biologic scaffolds on human stem cells and implications for CNS tissue engineering. *Tissue engineering Part A* 2014;20:313-23.

- [14] Wolf MT, Daly KA, Brennan-Pierce EP, Johnson SA, Carruthers CA, D'Amore A, et al. A hydrogel derived from decellularized dermal extracellular matrix. *Biomaterials* 2012;33:7028-38.
- [15] Sicari BM, Dziki JL, Siu BF, Medberry CJ, Dearth CL, Badylak SF. The promotion of a constructive macrophage phenotype by solubilized extracellular matrix. *Biomaterials* 2014;35:8605-12.
- [16] Wolf MT, Carruthers CA, Dearth CL, Crapo PM, Huber A, Burnsed OA, et al. Polypropylene surgical mesh coated with extracellular matrix mitigates the host foreign body response. *J Biomed Mater Res A* 2014;102:234-46.
- [17] Caicco MJ, Cooke MJ, Wang Y, Tuladhar A, Morshead CM, Shoichet MS. A hydrogel composite system for sustained epi-cortical delivery of Cyclosporin A to the brain for treatment of stroke. *Journal of controlled release : official journal of the Controlled Release Society* 2013;166:197-202.
- [18] Klose D, Laprais M, Leroux V, Siepmann F, Deprez B, Bordet R, et al. Fenofibrate-loaded PLGA microparticles: effects on ischemic stroke. *European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences* 2009;37:43-52.
- [19] Emerich DF, Silva E, Ali O, Mooney D, Bell W, Yu SJ, et al. Injectable VEGF hydrogels produce near complete neurological and anatomical protection following cerebral ischemia in rats. *Cell transplantation* 2010;19:1063-71.
- [20] Georges PC, Miller WJ, Meaney DF, Sawyer ES, Janmey PA. Matrices with compliance comparable to that of brain tissue select neuronal over glial growth in mixed cortical cultures. *Biophys J* 2006;90:3012-8.
- [21] Freytes DO, Martin J, Velankar SS, Lee AS, Badylak SF. Preparation and rheological characterization of a gel form of the porcine urinary bladder matrix. *Biomaterials* 2008;29:1630-7.
- [22] Zhang L, Zhang F, Weng Z, Brown BN, Yan H, Ma XM, et al. Effect of an inductive hydrogel composed of urinary bladder matrix upon functional recovery following traumatic brain injury. *Tissue engineering Part A* 2013;19:1909-18.
- [23] Saha K, Keung AJ, Irwin EF, Li Y, Little L, Schaffer DV, et al. Substrate modulus directs neural stem cell behavior. *Biophys J* 2008;95:4426-38.
- [24] Leipzig ND, Shoichet MS. The effect of substrate stiffness on adult neural stem cell behavior. *Biomaterials* 2009;30:6867-78.
- [25] Brady ML, Raghavan R, Alexander A, Kubota K, Sillay K, Emborg ME. Pathways of infusate loss during convection-enhanced delivery into the putamen nucleus. *Stereotactic and functional neurosurgery* 2013;91:69-78.
- [26] Valles F, Fiandaca MS, Bringas J, Dickinson P, LeCouteur R, Higgins R, et al. Anatomic compression caused by high-volume convection-enhanced delivery to the brain. *Neurosurgery* 2009;65:579-85; discussion 85-6.
- [27] Bible E, Chau DY, Alexander MR, Price J, Shakesheff KM, Modo M. Attachment of stem cells to scaffold particles for intra-cerebral transplantation. *Nature protocols* 2009;4:1440-53.
- [28] Naumova AV, Modo M, Moore A, Murry CE, Frank JA. Clinical imaging in regenerative medicine. *Nature biotechnology* 2014.
- [29] Crapo PM, Gilbert TW, Badylak SF. An overview of tissue and whole organ decellularization processes. *Biomaterials* 2011;32:3233-43.

- [30] Medberry CJ, Crapo PM, Siu BF, Carruthers CA, Wolf MT, Nagarkar SP, et al. Hydrogels derived from central nervous system extracellular matrix. *Biomaterials* 2013;34:1033-40.
- [31] Wolf MT, Daly KA, Brennan-Pierce EP, Johnson SA, Carruthers CA, D'Amore A, et al. A hydrogel derived from decellularized dermal extracellular matrix. *Biomaterials* 2012;33:7028-38.
- [32] Lu D, Mahmood A, Qu C, Hong X, Kaplan D, Chopp M. Collagen scaffolds populated with human marrow stromal cells reduce lesion volume and improve functional outcome after traumatic brain injury. *Neurosurgery* 2007;61:596-602; discussion -3.
- [33] Modo M, Stroemer RP, Tang E, Veizovic T, Sowniski P, Hodges H. Neurological sequelae and long-term behavioural assessment of rats with transient middle cerebral artery occlusion. *J Neurosci Methods* 2000;104:99-109.
- [34] Stille M, Smith EJ, Crum WR, Modo M. 3D reconstruction of 2D fluorescence histology images and registration with in vivo MR images: application in a rodent stroke model. *J Neurosci Methods* 2013;219:27-40.
- [35] Bible E, Qutachi O, Chau DY, Alexander MR, Shakesheff KM, Modo M. Neo-vascularization of the stroke cavity by implantation of human neural stem cells on VEGF-releasing PLGA microparticles. *Biomaterials* 2012;33:7435-46.
- [36] Paxinos G, Watson C. *The rat brain in stereotaxic coordinates*. 6th ed. Amsterdam, NL: Elsevier; 2007.
- [37] Rangel-Castilla L, Gopinath S, Robertson CS. Management of intracranial hypertension. *Neurologic clinics* 2008;26:521-41, x.
- [38] Badylak SF. The extracellular matrix as a biologic scaffold material. *Biomaterials* 2007;28:3587-93.
- [39] Aitken KJ, Bagli DJ. The bladder extracellular matrix. Part I: architecture, development and disease. *Nature reviews Urology* 2009;6:596-611.
- [40] Londono R, Badylak SF. Biologic scaffolds for regenerative medicine: mechanisms of in vivo remodeling. *Ann Biomed Eng* 2015;43:577-92.
- [41] Gilbert TW, Sellaro TL, Badylak SF. Decellularization of tissues and organs. *Biomaterials* 2006;27:3675-83.
- [42] Taylor Z, Miller K. Reassessment of brain elasticity for analysis of biomechanisms of hydrocephalus. *J Biomech* 2004;37:1263-9.
- [43] Gefen A, Margulies SS. Are in vivo and in situ brain tissues mechanically similar? *J Biomech* 2004;37:1339-52.
- [44] Aurand ER, Wagner J, Lanning C, Bjugstad KB. Building biocompatible hydrogels for tissue engineering of the brain and spinal cord. *J Funct Biomater* 2012;3:839-63.
- [45] Park KI, Teng YD, Snyder EY. The injured brain interacts reciprocally with neural stem cells supported by scaffolds to reconstitute lost tissue. *Nature biotechnology* 2002;20:1111-7.
- [46] Badylak SF, Valentin JE, Ravindra AK, McCabe GP, Stewart-Akers AM. Macrophage phenotype as a determinant of biologic scaffold remodeling. *Tissue engineering Part A* 2008;14:1835-42.
- [47] Brown BN, Londono R, Tottey S, Zhang L, Kukla KA, Wolf MT, et al. Macrophage phenotype as a predictor of constructive remodeling following the implantation

- of biologically derived surgical mesh materials. *Acta biomaterialia* 2012;8:978-87.
- [48] Brown BN, Valentin JE, Stewart-Akers AM, McCabe GP, Badylak SF. Macrophage phenotype and remodeling outcomes in response to biologic scaffolds with and without a cellular component. *Biomaterials* 2009;30:1482-91.
- [49] Agrawal V, Brown BN, Beattie AJ, Gilbert TW, Badylak SF. Evidence of innervation following extracellular matrix scaffold-mediated remodelling of muscular tissues. *J Tissue Eng Regen Med* 2009;3:590-600.
- [50] Agrawal V, Johnson SA, Reing J, Zhang L, Tottey S, Wang G, et al. Epimorphic regeneration approach to tissue replacement in adult mammals. *Proceedings of the National Academy of Sciences of the United States of America* 2010;107:3351-5.
- [51] Agrawal V, Tottey S, Johnson SA, Freund JM, Siu BF, Badylak SF. Recruitment of progenitor cells by an extracellular matrix cryptic peptide in a mouse model of digit amputation. *Tissue Eng Part A* 2011;17:2435-43.
- [52] Tan S, Fang JY, Yang Z, Nimni ME, Han B. The synergetic effect of hydrogel stiffness and growth factor on osteogenic differentiation. *Biomaterials* 2014;35:5294-306.
- [53] Wilkinson AE, Kobelt LJ, Leipzig ND. Immobilized ECM molecules and the effects of concentration and surface type on the control of NSC differentiation. *Journal of biomedical materials research Part A* 2013.
- [54] Qureshi NH, Bankiewicz KS, Louis DN, Hochberg FH, Chiocca EA, Harsh GR. Multicolumn infusion of gene therapy cells into human brain tumors: technical report. *Neurosurgery* 2000;46:663-8; discussion 8-9.
- [55] Yin D, Richardson RM, Fiandaca MS, Bringas J, Forsayeth J, Berger MS, et al. Cannula placement for effective convection-enhanced delivery in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics. *Journal of neurosurgery* 2010;113:240-8.
- [56] Yin D, Forsayeth J, Bankiewicz KS. Optimized cannula design and placement for convection-enhanced delivery in rat striatum. *Journal of neuroscience methods* 2010;187:46-51.
- [57] Agashi K, Chau DY, Shakesheff KM. The effect of delivery via narrow-bore needles on mesenchymal cells. *Regenerative medicine* 2009;4:49-64.
- [58] Kondziolka D, Gobbel GT, Fellows-Mayle W, Chang YF, Uram M. Injection parameters affect cell viability and implant volumes in automated cell delivery for the brain. *Cell transplantation* 2011;20:1901-6.
- [59] Brooks AI, Halterman MW, Chadwick CA, Davidson BL, Haak-Frendscho M, Radel C, et al. Reproducible and efficient murine CNS gene delivery using a microprocessor-controlled injector. *Journal of neuroscience methods* 1998;80:137-47.
- [60] Gobbel GT, Kondziolka D, Fellows-Mayle W, Uram M. Manual vs automated delivery of cells for transplantation: accuracy, reproducibility, and impact on viability. *Neurosurgery* 2010;67:1662-8; discussion 8.

- [61] Chan KM, Li RH, Chapman JW, Trac EM, Kobler JB, Zeitels SM, et al. Functionalizable hydrogel microparticles of tunable size and stiffness for soft-tissue filler applications. *Acta Biomater* 2014;10:2563-73.
- [62] Stowers RS, Allen SC, Suggs LJ. Dynamic phototuning of 3D hydrogel stiffness. *Proc Natl Acad Sci U S A* 2015;112:1953-8.
- [63] Ziv K, Nuhn H, Ben-Haim Y, Sasportas LS, Kempen PJ, Niedringhaus TP, et al. A tunable silk-alginate hydrogel scaffold for stem cell culture and transplantation. *Biomaterials* 2014;35:3736-43.

Figure Legends

Figure 1. Considerations for the injection of biomaterials into a stroke cavity. **A.** Injection of an insufficient quantity or local concentration of an 4 mg/mL ECM preparation leads to a poor gelation within the cavity and hence does not afford a complete and homogenous coverage (2 weeks post-MCAo, 24 hours post-injection). Although particles of ECM that formed accumulate at the border or damaged tissue (i), vast areas of host tissue and the cavity do not show any accumulation of ECM material (ii) indicating that concentration and volume of material is important to ensure proper coverage of the cavity. **B.** Trajectory for delivery through a needle requires careful planning based on in vivo non-invasive imaging. A trajectory for biomaterial delivery needs to avoid ventricular space, as it can lead to a puncture of the ventricular wall (yellow arrow) and the subsequent leakage of material into the ventricle. Such intraventricular leakage can lead to a decrease in biomaterial concentration in the cavity and an obstruction of cerebrospinal fluid (CSF) movement through the ventricle with potential damage to the choroid plexus. **C.** However, positioning of the injection tract to avoid the ventricle can damage critical neuroanatomical structures, such as the hippocampus, and lead to significant tissue tearing and backflow of biomaterial (i, red arrows). Placement of the cannula at the edge of the cavity can further damage already compromised tissue (white *), although it can deliver ECM material to the cavity. Nevertheless, an uneven distribution and heterogeneous concentration within the cavity (black *) can ensue with areas void of ECM containing extracellular fluid that has not been displaced (ii, white arrow). These

examples indicate the need for appropriate neurosurgical planning of biomaterial delivery to ensure a homogenous and complete distribution of ECM throughout the stroke cavity. (scale bars = 1 mm)

Figure 2. Injection-drainage of biomaterials and extracellular fluid. **A.** Delivery of material to the lesion cavity can be achieved by injection of a concentrate to be diluted in the extracellular fluid (ECF). For this, typically an injection site at the center of mass of the cavity is targeted (dotted green line = lesion cavity) [7, 27]. However, this delivery method can lead to variations in material concentration and especially in case of in situ gelation can produce areas void of biomaterial [11]. In contrast, the creation of a second burr hole allows displaced ECF to be drained while biomaterial is delivered. Placement of these ideally target the lower parts of the cavity for injection (to facilitate displacement) and crucially the drainage cannula needs to be positioned at the most dorsal part of the cavity to fully exploit the Archimedes principle of fluid displacement. **B.** For injection-drainage, T₂-weighted MRI scans were used to calculate the volume of the lesion cavity (hyperintense area), as well as to define coordinates for injection and drainage (AP=Anterior-Posterior; ML=Medio-Lateral; DV=Dorso-Ventral). **C.** Based on these coordinates, Burr holes were drilled into the skull at the appropriate location in relation to Bregma. **D.** Injection of a liquid hydrogel composed of extracellular matrix (ECM) through a needle/syringe fixed to the stereotactic device allowed injection of a volume equal to the lesion volume. As the biomaterial was denser than extracellular fluid (ECF), its injection led to the

displacement of ECF from the cavity through the drainage cannula. Gelation of the ECM occurred inside the cavity, allowing adaptation to the topology of the lesion. (scale bars = 2.5 mm)

Figure 3. Rheological characterization of ECM hydrogels. **A.** Viscosity of the ECM pre-gel at 10 °C was measured by applying a constant shear stress of 1 Pa. **B.** Representative curves of the ECM hydrogel gelation kinetics show the storage and loss modulus increase sigmoidally over time. Temperature is rapidly raised from 10 °C to 37 °C, and a small 0.5% oscillatory strain at a frequency of 1 rad/s was applied. **C.** Maximum storage modulus and loss modulus of the ECM hydrogel after gelation was complete at 37 °C. **D.** Gelation time of the ECM hydrogels to “50% gelation”, or time to 50% the maximum storage modulus. **E-F.** Representative graphs of the storage modulus, loss modulus, and complex viscosity of the ECM hydrogels at 4 mg/mL (E) and 8 mg/mL (F) plotted over angular frequencies on a log-log scale, measured at 37 °C by applying a small 0.5% oscillatory strain. * $p \leq 0.01$ ** $p \leq 0.001$

Figure 4. Detection of 8 mg/mL ECM hydrogel in the stroke cavity. **A.** The pig-specific collagen I antibody detects only the ECM hydrogel implanted into the stroke cavity, although there is some evidence of background autofluorescence and staining in damaged tissue. The non-specific collagen I antibody detects the implanted hydrogel with a very intense staining, but also stains host brain blood vessels as well as damaged tissue. The relatively high concentration of collagen I

in the ECM hydrogel compared to the host brain is evidenced by the short exposure times required to acquire images. The core of the implant is detected equally by the pig-specific and the non-specific antibody, but there are difference in their staining pattern **(i)**. Collagen I staining clearly allows a demarcation of the implant-host interface **(ii)**. Only the non-specific collagen I antibody detects rat collagen present in the basement membrane of host blood vessels in intact tissue **(iii)**. **B**. In a stroke brain injected with vehicle, there was no detection of pig-specific collagen I (only background fluorescence in the peri-infarct area). At the exposure time used for the ECM hydrogel (17 ms) there was no detection of any fluorescence of the non-specific antibody, but at a longer exposure time (200 ms), collagen I staining around the infarct cavity was evident. The pig-specific antibody can therefore be used to distinguish porcine-derived ECM implants versus rat host tissue with specific staining, but the ECM hydrogel can also be visualized macroscopically using the non-specific antibody by adjusting the exposure time for image acquisition. (scale bars = 1 mm)

Figure 5. Detection of 8 mg/mL ECM hydrogel using ECM markers. ECM contains a variety of molecules that can be detected using immunohistochemistry. The higher concentrations of molecules compared to brain tissue afford its detection using different antibodies against collagen IV, Hyaluronic acid, laminin and chondroitin sulfate. It is evident here that ECM molecules associated with glial scarring (collagen IV, chondroitin sulfate) and angiogenesis (laminin) are also highly expressed in the peri-infarct area and

hence not ideal for a selective detection of ECM hydrogel. However, hyaluronic acid also emerged as a potential alternative marker to collagen I, both of which are abundantly present with the (UBM)-ECM preparations compared to brain tissue. (scale bars = 500 μ m)

Figure 6. Correspondence between pre-implant MRI and post-mortem distribution of ECM hydrogel in the stroke cavity. **A.** Coverage of the lesion using this approach is demonstrated by immunohistochemistry 24 hours after injection. The lesion cavity is defined by glial scarring (GFAP), whereas the ECM hydrogel which contains high levels of collagen I can be detected using a collagen I antibody. It is remarkable that even within 24 hours there is cell invasion into the material from the host (DAPI). **B.** An overlay of the fluorescent histology images with the pre-implantation MRI indicates that indeed a good coverage of the cavity has been achieved. Nevertheless, it is noteworthy that the material did not completely cover the hyperintense area on the MRI, as tissue remnants were present in this region (blue arrows). This subtle difference is not evident based on the histological assessment alone and indicates that further improvements in non-invasive imaging are required to better define microenvironments present within the infarct territory. However, if there is an overestimation of injection volume, the drainage of superfluous material will prevent a buildup in the cavity. (scale bar = 2.5 mm)

Figure 7. Anterior-posterior images covering the tissue cavity caused by middle cerebral artery occlusion. **A.** The ECM hydrogel (8 mg/mL), as detected by collagen I staining (green), is fairly equally distributed throughout the cavity, defined by the lack of cells (DAPI staining in blue). Glial scarring (glial fibrillary acid protein in red) around the lesion cavity is also evident. The yellow dashed line indicates the point of injection, whereas the red dashed line depicts the position of the drainage cannula. In some areas, especially anteriorly **(i)**, some permeation of ECM hydrogel into the host brain was evident (yellow *), whereas in other areas (red *), small “particulates” of ECM were present within non-gelled areas of the cavity. A lack of hydrogel in some edge regions (white *) of the host-biomaterial interface was also evident indicating that some further optimization (e.g. speed of injection) of biomaterial distribution within the lesion can further improve coverage **(ii)**. **B.** The described approach produces fairly consistent coverage of the cavity, as can be seen in a further 4 examples. **C.** Still, further challenges for intracerebral delivery are apparent. Notably, the fragile peri-infarct tissue can be impacted by large volume injections of a high concentration of material (white arrows), whereas a denser material could also create a “clump” of material, leaving voids between host and material (red arrows), while a glial scar is forming (yellow arrows). By focusing on the tissue cavity, the peri-infarct tissue that is severely damaged (white *), but not lost, is not receiving biomaterial (red *). These aspects further highlight the importance of determining appropriate concentrations and speed of delivery to potentially

further improve the delivery of biomaterials to the damaged brain. (scale bars = 2.5 mm)

Figure 8. Concentration-dependent retention of ECM hydrogel in the lesion cavity. **A.** ECM hydrogel injection will only be retained within the lesion cavity if sufficient collagen I is present to afford gelation. Using the injection-drainage approach, it is possible to inject accurate concentration of ECM into the cavity and determine retention of the ECM hydrogel. A vehicle injection (0 mg/mL) of PBS indicated no collagen I-dependent detection (33 ms) of material inside the lesion cavity (as delineated by Iba1 staining for microglia) or the host brain. At 1 and 2 mg/mL ECM material mostly dissipated into the host brain, whereas at 3 mg/mL, ECM hydrogel was formed and retained within the cavity with some material gelling in the peri-infarct tissue. Higher than 3 mg/mL concentrations resulted in a gelation within the lesion cavity with little to no ECM hydrogel permeation into adjacent host tissue. (scale bar = 5 mm) **B.** At 1 mg/mL ECM injection, the injected material was only visible in the peri-infarct area. The pattern of distribution suggests permeation from the cavity. However, it is likely that some material was still present within the cavity and was lost upon sectioning due to a lack of structure (i.e. no gelation). (scale bar = 1 mm) **C.** At 3 mg/mL, gelation within the cavity occurred and this material was retained during sectioning, but it is also evident that some injected ECM material diffused into the damaged peri-infarct tissue potentially through the glial scar. Based on signal intensity, it is also possible to see a clear difference in collagen I content between

1 and 3 mg/mL. It is therefore important to note that not only is there a difference in “inductive” material being delivered, but the structural (i.e. gelation) properties of the ECM are also concentration dependent. (scale bar = 500 μ m)

Supplementary Material

Supplementary Figure 1. Measurement of midline shift and ECM hydrogel coverage of cavity. **A.** To measure potential changes in hemispheric volume and morphology, the central distance between the midline and the outer cortical border were measured for the ipsilateral hemisphere (red arrow), as well as the contralateral hemisphere (light blue arrow), with change expressed as % difference between both measurements. The same principle was applied to define changes in hemispheric area, where the area of the ipsilateral hemisphere (green outline) and contralateral hemisphere (yellow outline) were measured and compared. **B.** Measuring the coverage of ECM hydrogel of the lesion was achieved by drawing a Region of Interest over the cavity (in red), as well as the ECM hydrogel (in green), as detected by collagen I staining. The percentage coverage was hence calculated. In some cases, this revealed coverage larger than the cavity (i), whereas in others it revealed coverage that was smaller than the actual defect (ii). (DAPI=blue, Collagen I=green, scale bar = 1mm).

Supplementary Figure 2. A. Measurement of Intracranial pressure. Injection of ECM hydrogel with no drainage resulted in an increase in intracranial pressure. However, this increase was dissipated by drainage of fluid from the cyst. **B.** ECM coverage of the lesion cavity. The percent area of the lesion cavity covered by ECM hydrogel is compared for different concentrations of injections. It is evident that 1 and 2 mg/mL did not provide much gelation and retention, whereas concentrations >3 mg/mL provide extensive coverage (bars represent median values and error bars show the value range).

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Rheology

ECM
0 mg/ml
1 mg/ml
2 mg/ml
3 mg/ml
4 mg/ml
8 mg/ml

Injection - drainage

Gelation & Retention